Influence of dosage form on the intravitreal pharmacokinetics of diclofenac

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 10, 2009, Pages 4887-4897

  Durairaj, Chandrasekar ^a   Kim, Stephen J ^b   Edelhauser, Henry F ^c   Shah, Jaymin C ^d   Kompella, Uday B ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c EMORY EYE CENTER   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; SODIUM CHLORIDE; EYE DROPS; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOROID; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG TISSUE LEVEL; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SLOW RELEASE FORMULATION; SUSPENSION; TISSUE DISTRIBUTION; VITREOUS BODY; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG DOSAGE FORM; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; METABOLISM; RABBIT; RETINA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; CHOROID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DICLOFENAC; DOSAGE FORMS; HALF-LIFE; OPHTHALMIC SOLUTIONS; RABBITS; RETINA; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SUSPENSIONS; TISSUE DISTRIBUTION; VITREOUS BODY;

EID: 70349571743     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3565     Document Type: Article

References (29)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of agerelated macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-572.
2. Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122:552-563.
3. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina. 2000;20:244-250.
4. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003;121:57-61.
5. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology. 2005;112:139-143.
6. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002;16:438-440.
7. Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin. 2002;42:1-11.
8. Monnier Y, Zaric J, Ruegg C. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Curr Drug Targets Inflamm Allergy. 2005; 4:31-38.
9. Amrite AC, Edelhauser HF, Kompella UB. Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest Ophthalmol Vis Sci. 2008;49:320-332.
10. Costagliola C, Parmeggiani F, Antinozzi PP, Caccavale A, Cotticelli L, Sebastiani A. The influence of diclofenac ophthalmic solution on the intraocular pressure lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients. Exp Eye Res. 2005;81:610-615.
11. Rabiah PK, Fiscella RG, Tessler HH. Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Invest Ophthalmol Vis Sci. 1996;37:613-618.
12. Kothari HV, Lee WH, Ku EC. An alternate mechanism for regulation of leukotriene production in leukocytes: studies with an anti-inflammatory drug, sodium diclofenac. Biochim Biophys Acta. 1987;921:502-511.
13. Kim SJ, Adams NA, Toma HS, et al. Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study. Retina. 2008;28:595-605.
14. Durairaj C, Shah JC, Senapati S, Kompella UB. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res. 2009;26:1236-1260.
15. Jani PD, Singh N, Jenkins C, et al. Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci. 2007;48: 2030-2036.
16. Mo Y, Barnett ME, Takemoto D, Davidson H, Kompella UB. Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis. 2007;13:746-757.
17. Aukunuru JV, Sunkara G, Ayalasomayajula SP, DeRuiter J, Clark RC, Kompella UB. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm Res. 2002;19:278-285.
18. Kamppeter BA, Cej A, Jonas JB. Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye. Ophthalmology. 2008;115:1372-1375.
19. Menon IA, Wakeham DC, Persad SD, Avaria M, Trope GE, Basu PK. Quantitative determination of the melanin contents in ocular tissues from human blue and brown eyes. J Ocul Pharmacol. 1992; 8:35-42.
20. Cheruvu NP, Amrite AC, Kompella UB. Effect of eye pigmentation on transscleral drug delivery. Invest Ophthalmol Vis Sci. 2008;49: 333-341.
21. Park J, Bungay PM, Lutz RJ, et al. Evaluation of coupled convectivediffusive transport of drugs administered by intravitreal injection and controlled release implant. J Control Release. 2005;105:279-295.
22. Burnham KP, Anderson DR. Model Selection and Multi-model Inference: a Practical Information-Theoretic Approach. 2nd ed. New York: Springer; 2002:500.
23. Barbato F, Cappello B, La Rotonda MI, Miro A, Quaglia F. Diclofenac β-cyclodextrin binary systems: a study in solution and in the solid state. J Incl Phen Macr Chem. 2003;46:179-185.
24. Llinas A, Burley JC, Box KJ, Glen RC, Goodman JM. Diclofenac solubility: independent determination of the intrinsic solubility of three crystal forms. J Med Chem. 2007;50:979-983.
25. Kim H, Csaky KG, Gravlin L, et al. Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina. 2006;26:523-530.
26. Maurice D. Review: practical issues in intravitreal drug delivery. J Ocul Pharmacol Ther. 2001;17:393-401.
27. Algvere P, Bill A. Drainage of microspheres and RBCs from the vitreous of aphakic and phakic eyes. Arch Ophthalmol. 1979;97: 1333-1336.
28. Ohtori A, Tojo K. In vivo/in vitro correlation of intravitreal delivery of drugs with the help of computer simulation. Biol Pharm Bull. 1994;17:283-290.
29. Wagner JG, Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J Pharm Sci. 1964;53:1392-1403.